Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|October 1, 2020
Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled TrialMeir Mei-Zahav, Yulia Gendler, Elchanan Bruckheimer, et al.
Annals of Hematology|September 14, 2019
Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patientsBoaz Nachmias, Veronica Sandler, Elena Slyusarevsky, et al.
Leukemia & Lymphoma|October 21, 2016
The prognostic value of bone marrow involvement at the molecular level in aggressive lymphomaNeta Goldschmidt, Fares Darawshy, Geffen Kleinstern, et al.
Integrative Cancer Therapies|June 4, 2015
A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile NeutropeniaMoshe E Gatt, Jacob Strahilevitz, Nir Sharon, et al.
Leukemia & Lymphoma|January 29, 2019
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapseNeta Goldschmidt, Netanel A Horowitz, Vered Heffes, et al.
BMJ Quality & Safety|May 30, 2020
Limiting surveillance imaging for patients with lymphoma in remission: a mixed methods study leading to a Choosing Wisely recommendationOra Paltiel, Galor Raviv Sharabi, Reut Tzemach, et al.
Human Reproduction (Oxford, England)|July 6, 2023
Prior exposure to chemotherapy does not reduce the in vitro maturation potential of oocytes obtained from ovarian cortex in cancer patientsGilad Karavani, Koral Vedder, Einat Gutman-Ido, et al.
Oncotarget|November 22, 2017
MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphomaNir Pillar, Osnat Bairey, Neta Goldschmidt, et al.
British Journal of Haematology|December 10, 2013
Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual massEldad J Dann, Leanne Berkahn, Tatiana Mashiach, et al.
Haematologica|May 7, 2026
Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trialTamar Tadmor, Ohad Benjamini, Neta Goldschmidt, et al.
Pageof 8